Serological responses of mares and weanlings following vaccination with an inactivated whole virus equine herpesvirus 1 and equine herpesvirus 4 vaccine.
Equine herpesvirus 1 (EHV-1) is a major cause of respiratory disease and abortion in horses worldwide. Although some vaccines have been shown experimentally to reduce disease, there are few reports of the responses to vaccination in the field. This study measured antibody responses to vaccination of 159 mares (aged 4-17 years) and 101 foals (aged 3-6 months) on a large stud farm with a killed whole virus EHV-1/4 vaccine used as per the manufacturer's recommendations. Using an EHV glycoprotein D (gD)-specific ELISA and a type-specific glycoprotein G (gG) ELISA, respectively 13.8 and 28.9% of mares, and 42.6 and 46.6% of foals were classed as responding to vaccination. Additionally, 16.4 and 17.6% of mares were classified as persistently seropositive mares. Using both assays, responder mares and foals had lower week 0 mean ELISA absorbances than non-responder mares and foals. Responder mares were ten times more likely to have responder foals, and non-responder mares were six times more likely to have non-responder foals than other mares using the gG ELISA. Mares aged 7 years or less and foals aged 4 months or more were more likely to respond to vaccination than animals in other age groups. There was no association between response of mares and the number of previous vaccinations received and persistently seropositive mares did not respond to vaccination. This study documents the responses of mares and foals to vaccination in a large scale commercial environment in 2000, and suggests that knowledge of antibody status may allow a more selective vaccination strategy, representing considerable savings to industry.
Faculty of Veterinary Science, University of Sydney, 2006, New South Wales, Australia.
C E
CE
Foote
D N
DN
Love
J R
JR
Gilkerson
J M
JM
Whalley
D000367:Age Factors; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004197:Disease Reservoirs / Q000662:veterinary; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D004861:Herpesvirus 1, Equid / Q000254:growth & development / Q000276:immunology*; D023141:Herpesvirus 4, Equid / Q000254:growth & development / Q000276:immunology*; D006734:Horse Diseases / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D006736:Horses; D009517:New South Wales; D014611:Vaccination / Q000662:veterinary*; D014764:Viral Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology* / Q000592:standards
D000914:Antibodies, Viral; D014764:Viral Proteins; D014765:Viral Vaccines